Danish pharmaceutical large Novo Nordisk on Friday (December 12, 2025) launched Ozempic, a blockbuster injection for the remedy of sort 2 diabetes that’s common worldwide for its weight reduction results.
Ozempic is presently obtainable in India as 0.25 mg, 0.5 mg and 1 mg “FlexTouch Pen”. It’s an easy-to-use weekly pen gadget with a beginning worth of Rs 2,200 per week. Every pen incorporates 4 weekly doses, the corporate mentioned in an announcement in New Delhi.
Sufferers prescribed Ozempic injection will obtain 0.25 mg for 4 weeks and the full price can be ₹8,800.
Thereafter, as per the physician’s prognosis, the affected person will proceed to the following section – the ‘Step’ section, which prices Rs 10,170 at a dose of 0.5 mg for not less than 4 weeks, or the ‘Keep’ section, the place the month-to-month price is mounted at Rs 11,175 and a dose of 1 mg per week.
That is the second drug containing semaglutide as an energetic ingredient to be launched in India, after the corporate’s weight reduction drug Wegovy.
Wigoby, which was launched in India in June 2025, is indicated for persistent weight administration, whereas Novo Nordisk is positioning Ozempic as a weight-loss remedy for sort 2 diabetes, competing with Eli Lilly’s Mounjaro, which was launched in March this 12 months.
Vikrant Shrotriya, Managing Director, Novo Nordisk India, mentioned that by Ozempic, the corporate goals to supply sufferers with an modern and accessible remedy for the remedy of sort 2 diabetes, whereas additionally offering significant weight administration and long-term coronary heart and kidney safety.
“We’re very prudent by way of pricing in India. Providing at such costs remains to be very aggressive each internally and externally,” Shrotriya mentioned. P.T.I. When requested how Ozempic’s pricing in India compares with different world markets,
“I’d say it’s nonetheless inside the vary of affordability, however that is inside the vary of nations much like India,” he mentioned, including that Novo Nordisk sells Ozempic in India purely as a remedy for sort 2 diabetes.
“We utilized for sort 2 diabetes. We obtained approval (from India’s drug regulator),” he mentioned.
Relating to the sale of Ozempic in India, Shrotriya mentioned Novo Nordisk is working independently to make Ozempic obtainable throughout India.
He added that the corporate’s partnership with Emcure Pharma will proceed just for Wegoby’s second model in India, weight reduction drug Povizutra, semaglutide injection 2.4 mg.
Requested in regards to the market alternative for Ozempic in India, Shrotriya mentioned it’s tough to foretell as demand outstrips provide and globally as nicely, the market alternative for this drug is proving tough to foretell.
Ozempic’s launch in India was delayed partially to make sure uninterrupted provide, he mentioned, including that the shot can be imported from Denmark, the place it’s produced.
“We stay very agile and versatile by way of our provide chain serving India,” he mentioned.
He mentioned the corporate is prepared for competitors as generic drug producers are anticipated to enter the market because the patent for injectable semaglutide expires subsequent 12 months, and the corporate is assured that its product high quality and model energy will persuade sufferers to decide on its product.
Ozempic (semaglutide for injection) is run as soon as every week as an adjunct to food plan and train in adults dwelling with uncontrolled sort 2 diabetes mellitus (T2DM).
Citing World Well being Group estimates for 2023-24, the corporate introduced that 101 million individuals (roughly 11.4% of the inhabitants) stay with diabetes, making India the second-highest variety of diabetic sufferers on this planet after China.
He added that the nation has 136 million individuals with prediabetes and 254 million individuals with systemic weight problems, representing an accelerating well being problem that requires efficient, evidence-based remedies.
issued – December 12, 2025 7:50 PM IST
